SCHEMBL8209423

SCHEMBL8209423

CCOC(=O)C1OC1C(=O)N[C@@H](Cc1ccc(C)cc1)C(=O)NCc1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CAPN1 P07384 2/20 0.48
▸ CTSL P07711 6/20 0.45
▸ CTSB P07858 5/20 0.45
▸ PSMB1 P20618 1/20 0.45
▸ PSMB5 P28074 1/20 0.45
▸ PSMB2 P49721 1/20 0.45
▸ FCER2 P06734 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ CTSG P08311 1/20 0.45
▸ CTSS P25774 4/20 0.44
▸ MMP2 P08253 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP8 P22894 1/20 0.43
▸ ATM Q13315 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TACR1 P25103 1/20 0.42
▸ CTSK P43235 2/20 0.42
▸ PLG P00747 1/20 0.42
▸ PRSS1 P07477 1/20 0.42
▸ PRSS2 P07478 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14123427 1.00 CAPN1 (0.48) CAPN1CTSLCTSBPSMB1PSMB5
SCHEMBL14123223 1.00 CAPN1 (0.48) CAPN1CTSLCTSBPSMB1PSMB5
SCHEMBL14123387 0.89 CAPN1 (0.50) CAPN1CTSLCTSBPSMB1PSMB5
SCHEMBL8203656 0.89 CAPN1 (0.50) CAPN1CTSLCTSBPSMB1PSMB5
SCHEMBL8196251 0.89 CAPN1 (0.50) CAPN1CTSLCTSBPSMB1PSMB5
SCHEMBL15579554 0.88 CAPN1 (0.47) CAPN1CTSLCTSBPSMB5LMNA
SCHEMBL15579526 0.88 CAPN1 (0.47) CAPN1CTSLCTSBPSMB5LMNA
SCHEMBL14123205 0.86 PSMB1 (0.48) CTSLCTSBPSMB1PSMB5PSMB2
SCHEMBL8205231 0.86 PSMB1 (0.48) CTSLCTSBPSMB1PSMB5PSMB2
SCHEMBL8206608 0.86 PSMB1 (0.48) CTSLCTSBPSMB1PSMB5PSMB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-07-24 — — US disclosed
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-07-24 — — US disclosed
WO-2008042480-A2 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES SERPINB1, EPHX1, EPX CAPN1 199/4885CTSL 95/4885CTSB 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback